BlueRock Therapeutics | Company Profile
Contact Information
Industry & Market
Company Metrics
Funding Information
Headcount Distribution
By Department
Department Breakdown
Technology Stack
Analytics & Tracking
Video & Media
Email & Communication
Keywords & Focus Areas
BlueRock Therapeutics
Overview
BlueRock Therapeutics is a regenerative medicine company founded in 2016, focusing on stem cell technology to develop cell therapies for cardiovascular, neurodegenerative, and immunological diseases. It operates as a wholly owned subsidiary of Bayer AG since 2019 and was launched with significant financial backing, including a $225 million Series A financing.
The company utilizes its proprietary CELL+GENE™ platform, which employs induced pluripotent stem cells (iPSCs) to create authentic cell types for therapeutic use. This technology allows for the production of patient-matched or allogeneic cell therapies while avoiding ethical concerns associated with embryonic stem cells. Its research and development hubs are located in Toronto, New York City, and Cambridge, Massachusetts. The organization collaborates with leading academic and industrial partners to advance its product pipeline, focusing on therapies for neurodegenerative diseases like Parkinson's disease, cardiomyocyte-based treatments for heart failure, and immune cell therapies for immune-related conditions.
Basic Information
| Industry | research |
|---|---|
| Founded | 2016 |
| Revenue | $10.2M |
| Headquarters | 238 Main St, Cambridge, Massachusetts 02142-1008, United States |
| Parent Organization | Bayer |
Contact Details
- Phone: +1 857-299-7589
- Website: bluerocktx.com
- LinkedIn: linkedin.com/company/bluerocktx
Key Focus Areas & Initiatives
- Stem cell therapeutics
- Engineered cell therapy
- Cardiology and cardiology treatments
- Neurology and neurological disorders
- Immunology therapies
- Regenerative medicine and regenerative therapies
- Cell engineering & differentiation technology
- Cell replacement therapy
- Cell therapy for neurodegeneration and Parkinson's disease
- Biotechnology research and innovation
- Scalable GMP manufacturing
- Biopharmaceuticals and drug development
- Collaborative research with industry partners
- Clinical-stage cell therapy and clinical development
- Autologous and allogeneic cell therapy
- Cell therapy for autoimmune and immune-related diseases
- Cell therapy for ocular and retinal diseases
- Cell therapy for intractable diseases
- Disease modification strategies
- Personalized and innovative treatment options
Technologies Used
- Amazon AWS
- Amazon CloudFront
- BugHerd
- Google Tag Manager
- Gravity Forms
- Microsoft Office 365
- Mimecast
- Mobile Friendly
- Outlook
- Remote
- Route 53
- Vimeo
- WordPress.org
Community
